製品番号: HY-B0135S

Furosemide-d₅

Name: Furosemide-d5
Brand: MedChemExpress
SKU: HY-B0135S
Price: 500.00 USD
Availability: InStock
Rating: 5 (1 reviews)

カスタマーレビュー

Based on 1 Customer Validation

Furosemide-d₅ is the deuterated-labeled Furosemide (HY-B0135). Furosemide is an orally active NKCC2 inhibitor that can cross the blood-brain barrier. Furosemide inhibits NKCC1, NKCC2, KCC2, KCC3, and KCC4. Furosemide selectively antagonizes GABA_A receptors containing α6 and β2/3 or β3γ2 subunits. Furosemide penetrates the blood-brain barrier and blocks renal tubular sodium-chloride reabsorption, increases urinary excretion of sodium, chloride, potassium, and calcium, and activates the renin-angiotensin-aldosterone system. Furosemide can be used in research on congestive heart failure, hypertension, and edema.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度 : 99.85%
CAS 番号: 1189482-35-6
分子式: C₁₂H₆D₅ClN₂O₅S
分子量:335.77

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Furosemide-d₅ 構造式

CAS 番号: 1189482-35-6

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

体外実験

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Research Protocol for Cardiovascular Diseases

アプリケーション

1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.

化学情報

CAS 番号 1189482-35-6
非標識Cas 54-31-9
性状 Solid
分子量 335.77
分子式 C₁₂H₆D₅ClN₂O₅S
Color White to off-white
SMILES

OC(C1=C(C=C(C(S(N)(=O)=O)=C1)Cl)NC([2H])([2H])C2=C([2H])C([2H])=C([2H])O2)=O
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (297.82 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9782 mL

14.8911 mL

29.7823 mL

5 mM

0.5956 mL

2.9782 mL

5.9565 mL

10 mM

0.2978 mL

1.4891 mL

2.9782 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (295 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Tucker BJ, et al. Effect of furosemide administration on glomerular and tubular dynamics in the rat. Kidney international. 1984 Aug;26(2):112-21.

[2]. Mitchell JR, et al. Hepatic necrosis caused by furosemide. Nature. 1974 Oct 11;251(5475):508-11.

[3]. Das PK, et al. Furosemide Stress Test and Renal Resistive Index for Prediction of Severity of Acute Kidney Injury in Sepsis. Cureus. 2023 Aug;15(8):e44408.

[4]. Kelly MR, et al. Pharmacokinetics of orally administered furosemide. Clin Pharmacol Ther. 1974 Feb;15(2):178-86.

[5]. Inoue M, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney international. 1987 Aug;32(2):198-203.

[6]. McCurley JM, et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. Journal of the American College of Cardiology. 2004 Sep 15;44(6):1301-7.

[7]. Korpi ER, et al. Furosemide interactions with brain GABAA receptors. British journal of pharmacology. 1997 Mar;120(5):741-8.

[8]. Cataliotti A, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation. 2004 Apr 06;109(13):1680-5.

[9]. Duchin KL, et al. Effect of furosemide on renal autoregulation. Kidney Int. 1977 Dec;12(6):379-86. [Content Brief]

[10]. Orlov SN, et al. NKCC1 and NKCC2: The pathogenetic role of cation-chloride cotransporters in hypertension. Genes & diseases. 2015 Jun;2(2):186-196.

[11]. Limmer F, et al. Regulation of the Na(+)-K(+)-2Cl(-) cotransporter by cGMP/cGMP-dependent protein kinase I after furosemide administration. The FEBS journal. 2015 Oct;282(19):3786-98.

[12]. Suki WN, et al. Acute treatment of hypercalcemia with furosemide. N Engl J Med. 1970;283(16):836-840.

[13]. Osmanovic E, et al. The Effect of Furosemide on Arterial Blood Pressure, Blood Glucose Levels and Incidence of Heart Arrhythmias. American Journal of Internal Medicine. 2017;5(3):41-45.

[14]. Tenzing D, et al. Effect of furosemide in the treatment of high-altitude pulmonary edema. BMC Pulm Med. 2024 Mar 4;24(1):109.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9782 mL	14.8911 mL	29.7823 mL	74.4557 mL
	5 mM	0.5956 mL	2.9782 mL	5.9565 mL	14.8911 mL
	10 mM	0.2978 mL	1.4891 mL	2.9782 mL	7.4456 mL
	15 mM	0.1985 mL	0.9927 mL	1.9855 mL	4.9637 mL
	20 mM	0.1489 mL	0.7446 mL	1.4891 mL	3.7228 mL
	25 mM	0.1191 mL	0.5956 mL	1.1913 mL	2.9782 mL
	30 mM	0.0993 mL	0.4964 mL	0.9927 mL	2.4819 mL
	40 mM	0.0745 mL	0.3723 mL	0.7446 mL	1.8614 mL
	50 mM	0.0596 mL	0.2978 mL	0.5956 mL	1.4891 mL
	60 mM	0.0496 mL	0.2482 mL	0.4964 mL	1.2409 mL
	80 mM	0.0372 mL	0.1861 mL	0.3723 mL	0.9307 mL
	100 mM	0.0298 mL	0.1489 mL	0.2978 mL	0.7446 mL

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Furosemide-d₅

生物活性

製品説明

体外実験

アプリケーション

化学情報

溶剤 & 溶解度

体外:

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Keywords

最近チェックした製品

Furosemide-d5

生物活性

製品説明

体外実験

アプリケーション

化学情報

溶剤 & 溶解度

体外:

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Furosemide-d5 関連分類

HY-B0135S 関連分類

Bioz

Keywords

最近チェックした製品

Furosemide-d₅

Furosemide-d₅ 関連分類